Hypolipidemic effects of Nigella Sativa L. seeds oil in healthy volunteers

Hypolipidemic effects of Nigella Sativa L. Seeds oil in healthy volunteers: a randomized, double-blind, placebo-controlled clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201112271157N5

Enrollment

Registered

2012-01-05

Start date

2011-04-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteers. Other special examinations and investigations of persons without complaint or reported diagnosis

Interventions

Intervention 1: 2.5 ml black seed oil two times a day after meal for 8 weeks. Intervention 2: 2.5 ml mineral oil two times a day after meal for 8 weeks.

Treatment - Drugs

2.5 ml black seed oil two times a day after meal for 8 weeks

2.5 ml mineral oil two times a day after meal for 8 weeks

Eligibility

Sex/Gender

All

Age

25 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: healthy Iranian volunteers aged between 40 to 60 years; with fasting blood cholesterol 200 to 300 mg/dl; fasting blood glucose 80 to120 mg/dl and weight 55 to 85 kg

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Cholesterole. Timepoint: At starting of the study and after 8 weeks. Method of measurement: The fasting blood cholesterl level determined in laboratory.	—

Secondary

Measure	Time frame
SGPT. Timepoint: At starting of the study and after 8 weeks. Method of measurement: The fasting blood SGPT level determined in laboratory.;LDL. Timepoint: At starting of the study and after 8 weeks. Method of measurement: The fasting blood LDL level determined in laboratory.;Hba1c. Timepoint: At starting of the study and after 8 weeks. Method of measurement: The fasting blood Hba1c level determined in laboratory.;Glucose. Timepoint: At starting of the study and after 8 weeks. Method of measurement: The fasting blood Glucose level determined in laboratory.;Creatinine. Timepoint: At starting of the study and after 8 weeks. Method of measurement: The fasting blood Creatinine level determined in laboratory.;SGOT. Timepoint: At starting of the study and after 8 weeks. Method of measurement: The fasting blood SGOT level determined in laboratory.;BUN. Timepoint: At starting of the study and after 8 weeks. Method of measurement: The fasting blood BUN level determined in laboratory.;Triglyceride. Timepoint: At starting of the study and after 8 weeks. Method of measurement: determined in fasting blood sample in laboratory.;Hdl. Timepoint: At starting of the study and after 8 weeks. Method of measurement: determined in fasting blood sample in laboratory.	—

Measure

Time frame

SGPT. Timepoint: At starting of the study and after 8 weeks. Method of measurement: The fasting blood SGPT level determined in laboratory.;LDL. Timepoint: At starting of the study and after 8 weeks. Method of measurement: The fasting blood LDL level determined in laboratory.;Hba1c. Timepoint: At starting of the study and after 8 weeks. Method of measurement: The fasting blood Hba1c level determined in laboratory.;Glucose. Timepoint: At starting of the study and after 8 weeks. Method of measurement: The fasting blood Glucose level determined in laboratory.;Creatinine. Timepoint: At starting of the study and after 8 weeks. Method of measurement: The fasting blood Creatinine level determined in laboratory.;SGOT. Timepoint: At starting of the study and after 8 weeks. Method of measurement: The fasting blood SGOT level determined in laboratory.;BUN. Timepoint: At starting of the study and after 8 weeks. Method of measurement: The fasting blood BUN level determined in laboratory.;Triglyceride. Timepoint: At starting of the study and after 8 weeks. Method of measurement: determined in fasting blood sample in laboratory.;Hdl. Timepoint: At starting of the study and after 8 weeks. Method of measurement: determined in fasting blood sample in laboratory.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHassan Fallah Huseini

Institute of Medicinal Plants

huseini_fallah@yahoo.com+98 26 1476 4010

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026